Skip to main content
Erschienen in: EJNMMI Research 1/2023

Open Access 01.12.2023 | Original research

Relevance of 18F-DOPA visual and semi-quantitative PET metrics for the diagnostic of Parkinson disease in clinical practice: a machine learning-based inference study

verfasst von: Alex Iep, Mohammad B. Chawki, Lucas Goldfarb, Loc Nguyen, Vincent Brulon, Claude Comtat, Vincent Lebon, Florent L. Besson

Erschienen in: EJNMMI Research | Ausgabe 1/2023

Abstract

Purpose

To decipher the relevance of visual and semi-quantitative 6-fluoro-(18F)-L-DOPA (18F-DOPA) interpretation methods for the diagnostic of idiopathic Parkinson disease (IPD) in hybrid positron emission tomography (PET) and magnetic resonance imaging.

Material and methods

A total of 110 consecutive patients (48 IPD and 62 controls) with 11 months of median clinical follow-up (reference standard) were included. A composite visual assessment from five independent nuclear imaging readers, together with striatal standard uptake value (SUV) to occipital SUV ratio, striatal gradients and putamen asymmetry-based semi-quantitative PET metrics automatically extracted used to train machine learning models to classify IPD versus controls. Using a ratio of 70/30 for training and testing sets, respectively, five classification models—k-NN, LogRegression, support vector machine, random forest and gradient boosting—were trained by using 100 times repeated nested cross-validation procedures. From the best model on average, the contribution of PET parameters was deciphered using the Shapley additive explanations method (SHAP). Cross-validated receiver operating characteristic curves (cv-ROC) of the most contributive PET parameters were finally estimated and compared.

Results

The best machine learning model (k-NN) provided final cv-ROC of 0.81. According to SHAP analyses, visual PET metric was the most important contributor to the model overall performance, followed by the minimum between left and right striatal to occipital SUV ratio. The 10-time cv-ROC curves of visual, min SUVr or both showed quite similar performance (mean area under the ROC of 0.81, 0.81 and 0.79, respectively, for visual, min SUVr or both).

Conclusion

Visual expert analysis remains the most relevant parameter to predict IPD diagnosis at 11 months of median clinical follow-up in 18F-FDOPA. The min SUV ratio appears interesting in the perspective of simple semi-automated diagnostic workflows.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AUC
Area under the curve
cv-ROC
Cross-validated receiver operating characteristic curves
DAT
Dopamine transporter
IPD
Idiopathic Parkinson disease
FN
False negative
FP
False positive
18F-DOPA
6-Fluoro-(18F)-L-DOPA
MNI
Montreal neurological institute
MRI
Magnetic resonance imaging
PET
Positron emission tomography
SPECT
Single-photon emission computed tomography
SUV
Standard uptake value
SUVr
Standard uptake value ratio
TP
True positive
TN
True negative

Introduction

Idiopathic Parkinson disease (IPD) is the second neurodegenerative disorder worldwide, progressively affecting the deep brain dopaminergic pathways [1]. Because dopaminergic loss starts years before symptoms, the related clinical hallmarks—shaking, stiffness, and difficulty with coordination—may be subtle at very early stages, delaying definitive clinical diagnosis [24]. Although clinical and research diagnostic criteria for Parkinson disease have been updated in 2015 [57], the diagnostic confidence of IPD is still massively based on clinical follow-up and response to levodopa therapy, the new movement disorder society clinical diagnostic criteria for IPD being judged not useful by the experts in real-life practice [5]. Nuclear imaging has been shown a very useful complementary diagnostic tool [8], especially in atypical cases or at early stages of the disease. Dopaminergic PET imaging has gained progressive interest in practice, due to higher spatial resolution, faster acquisition procedure, improved dosimetry and cost-effectiveness compared to dopamine transporter (DAT) single photon emission computed tomography (SPECT) [9, 10]. As for DAT SPECT, visual assessment remains the most widely used interpretation method in practice [11]. Although simple static PET semi-quantification showed similar performance compared to PET kinetic procedures [12, 13], its diagnostic performance compared to visual assessment remains largely unexplored in 18F-DOPA PET imaging of IPD.
Taking advantage of emerging machine learning capabilities, the aim of this study was to robustly decipher the relevance of visual and semi-quantitative 18F-DOPA interpretation methods for the diagnostic of IPD in PET/MRI.

Material and methods

Population

In this monocentric controlled study, all consecutive patients addressed in our PET/MR imaging center for suspicion of Parkinsonism were screened from February 2018 to March 2020. From the initial database, 367 patients from 83 different doctors were retrieved. Fifteen neurologists out of the 25 ones who addressed at least four patients responded back. All the included patients fulfilled the following inclusion criteria: The clinical diagnosis was based on medical history, clinical symptoms (bradykinesia, rigidity, tremor), symptoms evolution under dopaminergic agonist; 11 months of median clinical follow-up between 18F-DOPA PET and the last consultation date was verified. Based on neurologists’ expertise, the clinical follow-up separated our population into two groups: clinically confirmed Parkinsonian syndrome and non-Parkinsonian syndromes (essential tremor, neuroleptic side-effects, non-Parkinsonian gait disorders). The cases of Parkinsonism still judged atypical after full multidisciplinary diagnostic work-up (in-laboratory video polysomnography, orthostatic hypotension test, specialized consultation in memory, neuro-psychologic test, assessment for dysarthria or swallowing trouble) were excluded from our study. A general overview of the selection process is provided in Fig. 1.

18F-DOPA PET/MRI protocol

All the included patients underwent hybrid brain imaging on the same 3-T PET/MRI system (Signa PET/MRI, GE Healthcare). The imaging protocol fulfilled the international guidelines [11], and all patients discontinued L-DOPA at least 12 h as recommended by manufacturers. A simultaneous single-bed PET/MRI acquisition of 10 min performed 1h30 after the intravenous injection of 1.5 MBq/kg of 18F-DOPA. During the PET acquisition, standard brain MR pulse sequences were performed, in particular: a zero time echo (ZTE) pulse sequence for MRI-based attenuation correction (matrix size: 128 × 128; flip angle: 5°; TE: 1.7 ms; TR: 4 ms; slice thickness: 2.78 mm) and a morphological 3D T1-weighted pulse sequence, BRAVO, matrix size: 256 × 226; flip angle: 15°; TE: 3.2 ms; TR: 8.5 ms; slice thickness: 1.2 mm). All the PET data were corrected from attenuation and reconstructed using an iterative algorithm, 3D TOF-OSEM, 8 iterations and 28 subsets with time of flight and point spread function modeling: matrix size 256 × 256 × 89, voxel size, 1.2 × 1.2 × 2.8 mm with a 3-mm Gaussian post-filtering.

Image processing, data extraction and preparation

An overview of image processing and analysis is provided in Fig. 2.
For the PET visual analysis, five experts in nuclear hybrid imaging, whose experience ranged from 6 to 12 years, independently reviewed all the PET/MRI on the same imaging workstation (ADW, version 4.7), all blinded to the final clinical diagnosis. For this purpose and using the predefined international criteria for 18F-DOPA PET imaging [11] with the same color scale, each expert realigned the data along the anterior to posterior corpus callosum axis, scaled the PET images to the rostral part of the putamen and carefully analyzed the distribution and intensity of 18F-DOPA uptake in the striatum (caudate and putamen) and background. For each case, the procedure was timed from the image opening to the end of the analysis process. Any asymmetry or decrease in uptake in the striate was considered pathological. A three-point scale normal (“− 1”), undetermined (“0”), and pathological (“1”) was first used, and the median score of the five readers represented the intermediate composite analysis of their expertise. In another session, readers altogether reviewed undetermined median score (“0”) cases to reach a consensus, and results were consequently attributed to all five readers to obtain a final composite binary output: normal or pathological. The final composite score was compared to the clinical standard reference for true positive (TP), false positive (FP), false negative (FN) and true negative (TN) rates.
For the semi-quantitative analyses, several PET metrics were automatically extracted by using FreeSurfer (v7.1.1), an open-source neuroimaging toolkit which provides advanced automated full processing streams for MRI and PET standardization and data extraction. T1-weighted MRI of all the patients was normalized to the Montreal neurological institute (MNI) reference space by using a complete neuro-imaging automated pipeline including nonlinear registration [1416], intensity correction [17] and skull stripping [18]. The cortical and subcortical brain structures were automatically segmented and labeled [19]. The Desikan–Killiany–Tourville segmentation mask was applied to the corresponding PET data without partial correction volume. From the segmented 18F-DOPA PET/MRI, SUVmean were automatically extracted by using the Freesurfer’s PET/MRI module named Petsurfer [20, 21]. Because the striatum contralateral to the most affected clinical side typically reflects the most altered SUV ratio in idiopathic Parkinson disease, the minimum SUVmean ratio of Freesurfer-based metrics showing between-group statistical significance on first-line descriptive analyses was retained because of their well-grounded physiopathological relevance: the minimum between \(\frac{{\text{Right striatum}}}{{\text{Occipital cortex}}}\) and \(\frac{{\text{Left striatum}}}{{\text{Occipital cortex}}}\) SUV ratio (min SUVr) [2224], the minimum between \(\frac{{\text{Right putamen}}}{{\text{Right caudate nucleus}}}\) and \(\frac{{\text{Left putamen}}}{{\text{Left caudate nucleus}}}\) SUV ratio (P/C gradient) [25], the minimum between \(\frac{{\text{Right posteriot putamen}}}{{\text{Right anterior putamen}}}\) and \(\frac{{\text{Left posteriot putamen}}}{{\text{Left anterior putamen}}}\) SUV ratio (intra-striatal gradient) [26] and asymmetry index [27] for Putamen SUVmean uptake, computed as follows: \(\frac{|{\text{Left Putamen-Right Putamen}}|}{{\text{Left Putamen+Right Putamen}}}\). Finally, potential collinearity between the five 18F-DOPA PET metrics (binary visual score and four semi-quantitative) was searched before machine learning procedures by using Spearman nonparametric measure of rank correlations.

Deciphering the contribution of 18F-DOPA PET parameters for the identification of IPD

The general framework of the statistical analyses is provided in Fig. 3. Considering the ultimate diagnosis retained by the neurologists at 11 months of median follow-up, five different embedded machine learning classifiers—k-nearest neighbors (k-NN), Log Regression with L1 and L2 regularization (Elastic Net, Log Reg), Support vector Machine (SVM), Random Forest (RF) and tree gradient boosting (XGBoost)—were learned patient-wise and compared on their capability to predict the final diagnosis of the patients based on the five selected 18F-DOPA PET metrics: binary visual score, min SUVr, P/C gradient, intra-striatal gradient and asymmetry index. For this purpose, the dataset was split into training and test sets with a 70%/30% ratio. To prevent overfitting and improve the robustness of the 5 models’ performance, a nested k-fold cross-validation was used during the training phase [28, 29]. For each model, the hyperparameters tuning was nested under the model selection (inner loop, k = 5), model which was assessed on random subsamples of the training set (outer loop, k = 10). The overall nested scheme was repeated 100 times. At the end, the best predictive model in average was applied on the testing set to provide unbiased optimized accuracy to predict the diagnosis of IPD. The explainability of the best model was assessed by using the Shapley additive explanations method (SHAP) (https://​christophm.​github.​io/​interpretable-ml-book/​shap.​html), which deciphers the contribution of each 18F-DOPA PET parameter. Finally, cross-validated ROC curves of the best model performance (k = 10) with the most relevant PET parameters were generated and compared. All the statistical analyses were performed with Python (version 3.8; Python Software Foundation) [30], using pandas, numpy, scipy, scikit learn and xgboost libraries.

Results

Population study

From the initial 367 patients addressed in our PET/MRI unit for suspicion of Parkinsonism, a total of 158 medical record has been reviewed. After accounting for excluded patients—lost in follow-up at review time (n = 21), who changed protocol because of MRI contraindications (n = 6), with atypical Parkinsonism (n = 18) and with unsegmentable brain due to severe atrophy in Freesurfer automatic process (n = 1) with lost data (n = 1)—a total of 110 patients were included. Finally, 110 patients were retained for the analyses, including 48 IPD and 62 patients considered clinically normal (control group). As illustrated in Table 1, no between-group statistical significance was observed for age, sex, nor clinical follow-up. Patients median age was 72 and 76 years old in IPD and control groups, respectively (p = 0.126). The IPD group sex ratio was imbalanced compared to the control group, but without statistical significance (M/F = 29/19 vs. 32/30; p = 0.360). The overall median clinical follow-up was 330 days, with longer duration for the IPD group compared to the control group (570 vs. 296 days, p = 0.054).
Table 1
Patients’ characteristics
 
Idiopathic Parkinson disease (IPD)
Control group
p value
Number of patients
48
62
Sex ratio M/F
29/19
32/30
0.360
Age (years)
   
          Median
72
76
0.126
           [IQR]
[67–79]
[69–82]
 
           [min–max]
[39–92]
[45–93]
 
Clinical follow duration (days)
   
           Median
570
296
0.054
           [IQR]
[215–730]
[116–501]
 
           [min–max]
[23–992]
[29–927]
 
IQR interquartile range

Image processing, data extraction and preparation

Results of readers final composite score are reported in Table 2. Considering a visual interpretation time of less than 2 min on average, the final composite score of the five readers provided 32/110 TP, 4/110 FP, 16/110 FN, and 58/110 TN, resulting in overall sensitivity, specificity, positive predictive value, and negative predictive value of 66,7%, 93.5%, 88.9%, and 78.4%, respectively. Two illustrative cases of visual analysis are provided in Fig. 4. The distribution of the four 18F-DOPA PET semi-quantitative metrics is illustrated in Fig. 5 and provided in Table 3. As predefined in the selection process, the between-groups differences were significant for the four semi-quantitative PET metrics. The inter-correlations between the five PET metrics (visual and four semi-quantitative PET metrics) ranged from − 0.75 (pair visual and intra-striatal gradient) to 0.61 (pair min SUVr and P/C gradient) (Fig. 6), all of them being statistically significant (Spearman rank test, p < 0.05).
Table 2
Readers visual analyses, majority vote results, and mean interpretation duration
 
Diagnostic performances
Mean interpretation duration (min) [95%CI]
Reader 1
TP = 30.0% (33/110)
FP = 3.6% (4/110)
1.09 [1.06–1.11]
 
FN = 13.6% (15/110)
TN = 52.7% (58/110)
 
Reader 2
TP = 29.1% (32/110)
FP = 3.6% (4/110)
0.99 [0.95–1.03]
 
FN = 14.5% (16/110)
TN = 52.7% (58/110)
 
Reader 3
TP = 28.2% (31/110)
FP = 3.6% (4/110)
1.44 [0.95–1.03]
 
FN = 15.5% (17/110)
TN = 52.7% (58/110)
 
Reader 4
TP = 28.2% (31/110)
FP = 10.9% (12/110)
1.97 [1.92–2.01]
 
FN = 15.5% (17/110)
TN = 45.5% (50/110)
 
Reader 5
TP = 20.0% (22/110)
FP = 2.7% (3/110)
0.7 [0.65–0.75]
 
FN = 23.6% (26/110)
TN = 53.6% (59/110)
 
Majority vote
TP = 29.1% (32/110)
FP = 3.6% (4/110)
1.24 [1.20–1.28]*
 
FN = 14.5% (16/110)
TN = 52.7% (58/110)
 
Mean interpretation time was expressed with 95% confidence interval [95%CI]
TP true positive, FP false positive, FN false negative, TN true negative
*Pooled mean interpretation duration across the five readers
Table 3
Characteristics of the semi-quantitative metrics extracted from normalized 18F-DOPA PET data
 
IPD
Controls
p value
Min SUVr median [IQR]
3.04 [2.81–3.34]
3.70 [3.37–4.07]
1.60 × 10−7
Asymmetry index median [IQR]
0.041 [0.019–0.083]
0.011 [0.005–0.021]
2.17 × 10−8
Putamen/caudate gradient median [IQR]
1.00 [0.85–1.15]
1.22 [1.13–1.30]
1.76 × 10−7
Min intra-striatal gradient median [IQR]
0.78 [0.73–0.89]
0.93 [0.89–0.96]
1.31 × 10−7
All ratios are unitless and expressed as median with interquartile range [IQR]

Deciphered contribution of 18F-DOPA PET parameters for the identification of IPD

None of the four PET metrics being highly correlated (Spearman \(\left|\rho \right|\) < 0.9), all were included as input in the machine learning procedures. As provided in Table 4, all the classifiers provided overall good performance to classify IPD and controls. The best classifier was on average the k-NN scheme. This model with fine-tuned hyperparameters provided final test area under the curve (AUC) of the cv-ROC of 0.81. SHAP analyses showed that visual PET metric was the most important contributor to the model overall performance, followed by the min SUVr (Fig. 7). Finally, the cross-validated ROC curves of visual, min SUVr or visual combined to min SUVr showed similar performance between visual or semi quantitative metrics (Fig. 8).
Table 4
Models’ performance on average, after 100 nested cross-validation procedures
Model
Mean accuracy (std)
k-NN
80.9 ± 1.55
Log regression (Elastic Net)
80 ± 1.44
Random forest
78.1 ± 2.25
SVM
78.4 ± 1.46
XGBoost
79.3 ± 2.5
After 100 iterations, the k-NN scheme was the best model on average

Discussion

In our controlled study including 110 participants with a median clinical follow-up reaching 11 months, the performance of five machine learning procedures with 100-time nested cross-validation were compared to accurately classify IPD from control. Our results demonstrated that among different well-grounded standard PET metrics, visual assessment and semi-quantitative min SUV ratio provided similar performance. In DAT SPECT, despite improvements with CZT systems, the spatial resolution and sensitivity detection remains lower than PET-CT systems, together with the lack of anatomical repairs for accurate realignment of the brain motivated the used of semi-quantitative ratios to limit inter reader variabilities. Although semi-quantification showed increased diagnostic performance in few SPECT studies [3133], such approach does not preclude from interobserver variations if performed manually or semi-automatically, and is still considered as an adjunct to visual analysis. Although aromatic l-amino acid decarboxylase (AADC) striatal deficiency can be quantified by PET dynamic acquisitions in Parkinsonian syndromes [34], practical consideration and similar diagnostic performance in cross-sectional studies have led to promote simpler SUV ratios. DAT SPECT and 18F-DOPA PET visual interpretation share similar features but have two different targets in dopaminergic neurotransmission that can decrease in parallel but not necessarily synchronously with progression of neurodegenerative Parkinsonism. In theory, in early IPD compensatory mechanisms trigger presynaptic DATs expression is downregulation, and l-amino acid decarboxylase upregulation which is was confirmed in a meta-analysis [22, 23, 25, 35] demonstrating that AADC defect seen with 18F-DOPA PET is consistently smaller than DAT defects in SPECT studies. Nevertheless both are able to diagnose presynaptic dopaminergic deficits in early phases of PD with excellent sensitivity and specificity [11], to our knowledge no study showed superiority of any procedure and compared to SPECT, 18F-DOPA PET provides higher detection sensitivity and spatial resolution, thus allowing very thinner visual assessment of deep brain structures involvement. In this context, and except for particular follow-up study purpose [3639], justifying semi-quantification or more sophisticated methods over visual assessment to diagnose Parkinsonism remains largely under evaluated in clinical practice. In the era of precision medicine, the search for new powerful and robust imaging biomarkers constitutes a very hot topic of interest in a wide variety of diseases. In this context, automated image processing workflows have emerged, and could facilitate the interpretation of physicians in daily practice. Motivated by its rational in high spatially resolved morphological imaging, radiomics gradually invades nuclear imaging of oncological and non-oncological diseases, including Parkinsonian syndromes [4044]. In their very recent paper, Comte et al. trained and validated a logistic regression model with L1 regularization to identify dopaminergic denervation on 18F-DOPA PET/CT [44]. Among 43 first and higher-orders parameters, three textural features were found to identify abnormal 18F-DOPA PET almost as well as a nuclear imaging expert, considered here as the gold standard and study outcome. As mentioned by the authors, the clinical utility of such approach remains unknown, also questioning its conceptual diagnostic relevance in this particular topic, given the limited semiology of 18F-DOPA PET pattern abnormalities, and the well-known major logistical drawbacks of handcrafted radiomic pipelines in real-life practice. Recently, the clinical utility of deep-learning based methods to identify Parkinson disease directly from PET data has been emphasized, with very promising results [4547]. Deep learning conceptually tackles all the limitations of handcrafted radiomics procedures and would probably constitute a more powerful and efficient alternative to human expert reading for basic imaging identification tasks. In this way, capturing the objective min SUVr from striata, which was here as relevant as visual expert assessment, appears a promising way toward simple assisted analysis workflows. However, multicentric studies are mandatory to overcome the lack of reproducibility of standard PET semi-quantitative metrics related to PET systems image reconstruction properties (the well-known center effect). In accordance with the recent EANM guidelines [11] visual analysis remains to date the most relevant parameter to predict IPD.
Our study has several limitations. Firstly, the median follow-up of 11 months could have led to potential diagnostic misclassification [48]. Because the new movement disorder society clinical diagnostic criteria [6] are currently being judged not useful by the experts in real-life practice [5] trained neurologists typically make the diagnosis on medical history, clinical symptoms (bradykinesia, rigidity, tremor) and symptoms evolution under treatment. In atypical cases, staff of experts make their conclusions on a full multidisciplinary work-up. Second, our study included outpatients with mild -early symptoms mainly, for whom clinical diagnosis was ambiguous, justifying the 18F-DOPA imaging (in the case of cardinal symptoms, in particular at advanced stages, dopaminergic imaging has no clinical relevance). Because our patients did not have clinical confirmation yet at the time of 18F-DOPA PET imaging, the severity score of IPD was not provided at this time, emphasizing the real-life practice conditions of our study. To note, this study was not designed for the PET assessment of disease clinical severity, which is out of the scope of this study and has been widely studied by the past. Third, from hundreds of quantitative morphological and metabolic measures available with Freesurfer and Petsurfer neuroimaging pipeline, only few semi-quantitative metabolic PET metrics were considered clinically relevant given the physiopathology of dopaminergic denervation of striate: SUV metabolic ratios, gradient, and asymmetry indices. This choice was motivated by the fact that (1) we wanted to compare different well-known and usable PET metrics that are easily applicable in routine practice, and more importantly transposable to the individual level which contrasts with recent radiomics studies published; (2) making statistical inference with less than 10 participants per parameter becomes conceptually unacceptable [49, 50]. Forth, the selected semi-quantitative features were competing with the median performance of five experts that blindly and independently reviewed each case to limit inter-readers potential heterogeneity. One strength of future machine learning model in this context could be the reproducibility of predictions compared to a single expert reading. The main asset in our study is the use of simultaneous PET/MRI acquisition, which improves striatal segmentation from T1-weighted sequence over PET images [51]. Nevertheless, the potential of MRI cannot be restrained to morphological analysis. Promising results showed high correlation between Parkinson disease and specific MRI-multiparametric brainstem investigation [52], in particular the iron deposit in the substantia nigra. Recent results also showed correlation between iron deposit in substantia nigra and striatal dopamine denervation seen with 18F-DOPA PET [53, 54]. All these results may promote further research to better capture the relevance of combining 18F-DOPA and MRI capabilities in this field.

Conclusion

Visual expert analysis remains the most relevant parameter to predict IPD diagnosis at 11 months of median clinical follow-up in 18F-DOPA. The min SUV ratio appears interesting in the perspective of simple semi-automated diagnostic workflows.

Acknowledgements

The authors would like to thank our corresponding neurologists Anne De Recondo, François Lun, Amer-Adam Al Najar Carpentier, Jerome Blin, Valerie Bourdinaud, Ludovic Morin, Harisoa Andriatsiferana, Andre Ferreira, Marie-Anne Deschiens. The authors also would like to particularly thank Ghislaine Latapie, Vanessa Perier, Christine Manciot, Bérangère Eyl, Claire Heronneau, Marion Petit, Elizabeth Mendes, Yoann Fontyn, Kevin Phansavath from the Service Hospitalier Frédéric Joliot-CEA for their help in completing this study.

Declarations

This study has been approved by local ethic committee of the service hospitalier Frédéric Joliot, reference number: codir-shfj 210122, and the study has been conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants or if participants are under 16, from a parent and/or legal guardian.
Written informed consent was obtained from the patient for publication of this study and accompanying images.

Competing interests

The authors have no relevant financial or nonfinancial interests to disclose.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primer. 2017;3:17013.CrossRef Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primer. 2017;3:17013.CrossRef
2.
Zurück zum Zitat Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969.CrossRefPubMed Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969.CrossRefPubMed
3.
Zurück zum Zitat Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18:467–86.CrossRefPubMed Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18:467–86.CrossRefPubMed
4.
Zurück zum Zitat Felicio AC, Shih MC, Godeiro-Junior C, Andrade LAF, Bressan RA, Ferraz HB. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist. 2009;15:6–16.CrossRefPubMed Felicio AC, Shih MC, Godeiro-Junior C, Andrade LAF, Bressan RA, Ferraz HB. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist. 2009;15:6–16.CrossRefPubMed
5.
Zurück zum Zitat Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front Neurol. 2018;9:156.CrossRefPubMedPubMedCentral Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front Neurol. 2018;9:156.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease: MDS-PD clinical diagnostic criteria. Mov Disord. 2015;30:1591–601.CrossRefPubMed Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease: MDS-PD clinical diagnostic criteria. Mov Disord. 2015;30:1591–601.CrossRefPubMed
7.
Zurück zum Zitat Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease: MDS criteria for prodromal PD. Mov Disord. 2015;30:1600–11.CrossRefPubMed Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease: MDS criteria for prodromal PD. Mov Disord. 2015;30:1600–11.CrossRefPubMed
8.
Zurück zum Zitat Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Italy. 2012;56:17–26. Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Italy. 2012;56:17–26.
9.
Zurück zum Zitat Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5:75–86.CrossRefPubMed Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5:75–86.CrossRefPubMed
10.
Zurück zum Zitat Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134:3146–66.CrossRefPubMed Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134:3146–66.CrossRefPubMed
11.
Zurück zum Zitat Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.CrossRefPubMedPubMedCentral Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Otsuka M, Ichiya Y, Kuwabara Y, Fukumura T, Sasaki M, Masuda K. Evaluation of the ratio method compared with graphical analyses for estimating nigrostriatal function in human 18F-dopa PET studies with or without carbidopa. Nucl Med Commun. 1993;14:862–7.CrossRefPubMed Otsuka M, Ichiya Y, Kuwabara Y, Fukumura T, Sasaki M, Masuda K. Evaluation of the ratio method compared with graphical analyses for estimating nigrostriatal function in human 18F-dopa PET studies with or without carbidopa. Nucl Med Commun. 1993;14:862–7.CrossRefPubMed
13.
Zurück zum Zitat Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med Off Publ Soc Nucl Med. 1994;35:955–63. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med Off Publ Soc Nucl Med. 1994;35:955–63.
14.
Zurück zum Zitat Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11–22.CrossRefPubMed Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11–22.CrossRefPubMed
15.
Zurück zum Zitat Dale A, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179–94.CrossRefPubMed Dale A, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179–94.CrossRefPubMed
16.
Zurück zum Zitat Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2000;97:11050–5.CrossRefPubMedPubMedCentral Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2000;97:11050–5.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87–97.CrossRefPubMed Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87–97.CrossRefPubMed
18.
Zurück zum Zitat Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage. 2004;22:1060–75.CrossRefPubMed Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage. 2004;22:1060–75.CrossRefPubMed
19.
Zurück zum Zitat Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.CrossRefPubMed Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.CrossRefPubMed
20.
Zurück zum Zitat Greve DN, Svarer C, Fisher PM, Feng L, Hansen AE, Baare W, et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage. 2014;92:225–36.CrossRefPubMed Greve DN, Svarer C, Fisher PM, Feng L, Hansen AE, Baare W, et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage. 2014;92:225–36.CrossRefPubMed
21.
Zurück zum Zitat Greve DN, Salat DH, Bowen SL, Izquierdo-Garcia D, Schultz AP, Catana C, et al. Different partial volume correction methods lead to different conclusions: an 18F-FDG-PET study of aging. Neuroimage. 2016;132:334–43.CrossRefPubMed Greve DN, Salat DH, Bowen SL, Izquierdo-Garcia D, Schultz AP, Catana C, et al. Different partial volume correction methods lead to different conclusions: an 18F-FDG-PET study of aging. Neuroimage. 2016;132:334–43.CrossRefPubMed
22.
Zurück zum Zitat Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med Off Publ Soc Nucl Med. 2002;43:1324–30. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med Off Publ Soc Nucl Med. 2002;43:1324–30.
23.
Zurück zum Zitat Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med Off Publ Soc Nucl Med. 2009;50:893–9. Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med Off Publ Soc Nucl Med. 2009;50:893–9.
24.
Zurück zum Zitat Oehme L, Perick M, Beuthien-Baumann B, Wolz M, Storch A, Löhle M, et al. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1550–9.CrossRefPubMed Oehme L, Perick M, Beuthien-Baumann B, Wolz M, Storch A, Löhle M, et al. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1550–9.CrossRefPubMed
25.
Zurück zum Zitat Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. J Neurol Sci. 1996;136:169–73.CrossRefPubMed Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. J Neurol Sci. 1996;136:169–73.CrossRefPubMed
26.
Zurück zum Zitat Stormezand GN, Chaves LT, Vállez García D, Doorduin J, De Jong BM, Leenders KL, et al. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. NeuroImage Clin. 2020;25:102161.CrossRefPubMedPubMedCentral Stormezand GN, Chaves LT, Vállez García D, Doorduin J, De Jong BM, Leenders KL, et al. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. NeuroImage Clin. 2020;25:102161.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Contrafatto D, Mostile G, Nicoletti A, Dibilio V, Raciti L, Lanzafame S, et al. [123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism: SPECT in differential diagnosis of vascular parkinsonism. Acta Neurol Scand. 2012;126:12–6.CrossRefPubMed Contrafatto D, Mostile G, Nicoletti A, Dibilio V, Raciti L, Lanzafame S, et al. [123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism: SPECT in differential diagnosis of vascular parkinsonism. Acta Neurol Scand. 2012;126:12–6.CrossRefPubMed
28.
Zurück zum Zitat Cawley GC, Talbot NLC. On over-fitting in model selection and subsequent selection bias in performance evaluation. J Mach Learn Res. 2010;11:2079–107. Cawley GC, Talbot NLC. On over-fitting in model selection and subsequent selection bias in performance evaluation. J Mach Learn Res. 2010;11:2079–107.
29.
Zurück zum Zitat Krstajic D, Buturovic LJ, Leahy DE, Thomas S. Cross-validation pitfalls when selecting and assessing regression and classification models. J Cheminform. 2014;6:10.CrossRefPubMedPubMedCentral Krstajic D, Buturovic LJ, Leahy DE, Thomas S. Cross-validation pitfalls when selecting and assessing regression and classification models. J Cheminform. 2014;6:10.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Van Rossum G, Drake FL Jr. Python/C API reference manual. Wilmington: Python Software Foundation; 2002. Van Rossum G, Drake FL Jr. Python/C API reference manual. Wilmington: Python Software Foundation; 2002.
31.
Zurück zum Zitat Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med Off Publ Soc Nucl Med. 1998;39:1500–8. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med Off Publ Soc Nucl Med. 1998;39:1500–8.
32.
Zurück zum Zitat Arnaldi D, Campus C, Ferrara M, Famà F, Picco A, De Carli F, et al. What predicts cognitive decline in de novo Parkinson’s disease? Neurobiol Aging. 2012;33(1127):e11-20. Arnaldi D, Campus C, Ferrara M, Famà F, Picco A, De Carli F, et al. What predicts cognitive decline in de novo Parkinson’s disease? Neurobiol Aging. 2012;33(1127):e11-20.
33.
Zurück zum Zitat Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, et al. [123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys. 2017;4:8.CrossRefPubMedPubMedCentral Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, et al. [123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys. 2017;4:8.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Kuwabara H, Cumming P, Yasuhara Y, Léger GC, Guttman M, Diksic M, et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson’s disease. J Nucl Med Off Publ Soc Nucl Med. 1995;36:1226–31. Kuwabara H, Cumming P, Yasuhara Y, Léger GC, Guttman M, Diksic M, et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson’s disease. J Nucl Med Off Publ Soc Nucl Med. 1995;36:1226–31.
35.
Zurück zum Zitat Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol. 2017;82:873–82.CrossRefPubMed Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol. 2017;82:873–82.CrossRefPubMed
36.
Zurück zum Zitat Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995;59:597–600.CrossRefPubMedPubMedCentral Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995;59:597–600.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.CrossRefPubMedPubMedCentral Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.CrossRefPubMed Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.CrossRefPubMed
39.
Zurück zum Zitat Lin C-H, Chang C-H, Tai C-H, Cheng M-F, Chen Y-C, Chao Y-T, et al. A double-blind, randomized, controlled trial of lovastatin in early-stage Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2021;36:1229–37.CrossRef Lin C-H, Chang C-H, Tai C-H, Cheng M-F, Chen Y-C, Chao Y-T, et al. A double-blind, randomized, controlled trial of lovastatin in early-stage Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2021;36:1229–37.CrossRef
40.
Zurück zum Zitat Martinez-Murcia FJ, Górriz JM, Ramírez J, Moreno-Caballero M, Gómez-Río M. The Parkinson’s progression markers initiative. Parametrization of textural patterns in 123I-ioflupane imaging for the automatic detection of parkinsonism: parametrization of textural patterns in 123I-ioflupane imaging. Med Phys. 2013;41:012502.CrossRef Martinez-Murcia FJ, Górriz JM, Ramírez J, Moreno-Caballero M, Gómez-Río M. The Parkinson’s progression markers initiative. Parametrization of textural patterns in 123I-ioflupane imaging for the automatic detection of parkinsonism: parametrization of textural patterns in 123I-ioflupane imaging. Med Phys. 2013;41:012502.CrossRef
41.
Zurück zum Zitat Rahmim A, Salimpour Y, Jain S, Blinder SAL, Klyuzhin IS, Smith GS, et al. Application of texture analysis to DAT SPECT imaging: relationship to clinical assessments. NeuroImage Clin. 2016;12:e1-9.CrossRefPubMedPubMedCentral Rahmim A, Salimpour Y, Jain S, Blinder SAL, Klyuzhin IS, Smith GS, et al. Application of texture analysis to DAT SPECT imaging: relationship to clinical assessments. NeuroImage Clin. 2016;12:e1-9.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Rahmim A, Huang P, Shenkov N, Fotouhi S, Davoodi-Bojd E, Lu L, et al. Improved prediction of outcome in Parkinson’s disease using radiomics analysis of longitudinal DAT SPECT images. NeuroImage Clin. 2017;16:539–44.CrossRefPubMedPubMedCentral Rahmim A, Huang P, Shenkov N, Fotouhi S, Davoodi-Bojd E, Lu L, et al. Improved prediction of outcome in Parkinson’s disease using radiomics analysis of longitudinal DAT SPECT images. NeuroImage Clin. 2017;16:539–44.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Wu Y, Jiang J-H, Chen L, Lu J-Y, Ge J-J, Liu F-T, et al. Use of radiomic features and support vector machine to distinguish Parkinson’s disease cases from normal controls. Ann Transl Med. 2019;7:773.CrossRefPubMedPubMedCentral Wu Y, Jiang J-H, Chen L, Lu J-Y, Ge J-J, Liu F-T, et al. Use of radiomic features and support vector machine to distinguish Parkinson’s disease cases from normal controls. Ann Transl Med. 2019;7:773.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Dai Y, Tang Z, Wang Y, Xu Z. Data driven intelligent diagnostics for Parkinson’s disease. IEEE Access. 2019;7:106941–50.CrossRef Dai Y, Tang Z, Wang Y, Xu Z. Data driven intelligent diagnostics for Parkinson’s disease. IEEE Access. 2019;7:106941–50.CrossRef
46.
Zurück zum Zitat Shen T, Jiang J, Lin W, Ge J, Wu P, Zhou Y, et al. Use of overlapping group LASSO sparse deep belief network to discriminate Parkinson’s disease and normal control. Front Neurosci. 2019;13:396.CrossRefPubMedPubMedCentral Shen T, Jiang J, Lin W, Ge J, Wu P, Zhou Y, et al. Use of overlapping group LASSO sparse deep belief network to discriminate Parkinson’s disease and normal control. Front Neurosci. 2019;13:396.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Piccardo A, Cappuccio R, Bottoni G, Cecchin D, Mazzella L, Cirone A, et al. The role of the deep convolutional neural network as an aid to interpreting brain [(18)F]DOPA PET/CT in the diagnosis of Parkinson’s disease. Eur Radiol. 2021;31:7003–11.CrossRefPubMed Piccardo A, Cappuccio R, Bottoni G, Cecchin D, Mazzella L, Cirone A, et al. The role of the deep convolutional neural network as an aid to interpreting brain [(18)F]DOPA PET/CT in the diagnosis of Parkinson’s disease. Eur Radiol. 2021;31:7003–11.CrossRefPubMed
48.
Zurück zum Zitat Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566–76.CrossRefPubMed Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566–76.CrossRefPubMed
49.
Zurück zum Zitat Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 2015;13:1.CrossRefPubMedPubMedCentral Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 2015;13:1.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Struck AF, Hall LT, Kusmirek JE, Gallagher CL, Floberg JM, Jaskowiak CJ, et al. (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison. Am J Nucl Med Mol Imaging. 2012;2:475–82.PubMedPubMedCentral Struck AF, Hall LT, Kusmirek JE, Gallagher CL, Floberg JM, Jaskowiak CJ, et al. (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison. Am J Nucl Med Mol Imaging. 2012;2:475–82.PubMedPubMedCentral
52.
Zurück zum Zitat Arribarat G, De Barros A, Péran P. Modern brainstem MRI techniques for the diagnosis of Parkinson’s disease and parkinsonisms. Front Neurol. 2020;11:791.CrossRefPubMedPubMedCentral Arribarat G, De Barros A, Péran P. Modern brainstem MRI techniques for the diagnosis of Parkinson’s disease and parkinsonisms. Front Neurol. 2020;11:791.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Depierreux F, Parmentier E, Mackels L, Baquero K, Degueldre C, Balteau E, et al. Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. NPJ Park Dis. 2021;7:57.CrossRef Depierreux F, Parmentier E, Mackels L, Baquero K, Degueldre C, Balteau E, et al. Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. NPJ Park Dis. 2021;7:57.CrossRef
54.
Zurück zum Zitat Kathuria H, Mehta S, Ahuja CK, Chakravarty K, Ray S, Mittal BR, et al. Utility of imaging of nigrosome-1 on 3T MRI and its comparison with 18F-DOPA PET in the diagnosis of idiopathic Parkinson disease and atypical parkinsonism. Mov Disord Clin Pract. 2021;8:224–30.CrossRefPubMed Kathuria H, Mehta S, Ahuja CK, Chakravarty K, Ray S, Mittal BR, et al. Utility of imaging of nigrosome-1 on 3T MRI and its comparison with 18F-DOPA PET in the diagnosis of idiopathic Parkinson disease and atypical parkinsonism. Mov Disord Clin Pract. 2021;8:224–30.CrossRefPubMed
Metadaten
Titel
Relevance of 18F-DOPA visual and semi-quantitative PET metrics for the diagnostic of Parkinson disease in clinical practice: a machine learning-based inference study
verfasst von
Alex Iep
Mohammad B. Chawki
Lucas Goldfarb
Loc Nguyen
Vincent Brulon
Claude Comtat
Vincent Lebon
Florent L. Besson
Publikationsdatum
01.12.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
EJNMMI Research / Ausgabe 1/2023
Elektronische ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-023-00962-x

Weitere Artikel der Ausgabe 1/2023

EJNMMI Research 1/2023 Zur Ausgabe